Literature DB >> 25477567

Assessment of the intensive care unit treatment of pneumonia at a veterans affairs facility.

Carrie L Griffiths1, Steven Pass2, W Claibe Yarbrough3.   

Abstract

INTRODUCTION: Pneumonia is a common cause of morbidity and mortality in the critically ill. Clinicians use a range of duration for antibiotic treatment from 7 to 14 days or longer. Failure to de-escalate antimicrobial therapy in a timely manner may lead to increased antimicrobial resistance, increased risk of side effects, and increased cost.
OBJECTIVE: To investigate potential methods to improve treatment of pneumonia for patients in 4 intensive care units (ICUs).
METHODS: A retrospective descriptive chart review was conducted at the Veterans Affairs North Texas Health Care System (VANTHCS). Veterans aged 18 to 90 years admitted to the ICU with a diagnosis of pneumonia were included. Descriptive statistics were used to interpret the data. Current management was reviewed to identify markers such as length of antibiotic therapy, ICU length of stay, and inpatient mortality. Secondary objectives included appropriateness and accuracy of the empiric regimen.
RESULTS: Of the 1,854 Veterans admitted, 107 met inclusion criteria. Antibiotic choices for positive cultures were appropriate in 45 out of 46 (98%) patients, with an average length of therapy of 8.6 ± 6.3 days. De-escalation of antibiotics based on sensitivity data occurred in 73% of positive cultures.
CONCLUSIONS: Pneumonia in the VANTHCS ICUs is initially treated with empiric antibiotics. Empiric antibiotic therapy for pneumonia was appropriate and accurate over this time period. Opportunities exist for de-escalation in patients with or without positive cultures. The procalcitonin assay is now being utilized at VANTHCS to optimize patient care.

Entities:  

Keywords:  antibiotics; de-escalation; pneumonia

Year:  2014        PMID: 25477567      PMCID: PMC4252218          DOI: 10.1310/hpj4910-950

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  7 in total

Review 1.  Ventilator-associated pneumonia. Diagnosis, pathogenesis and prevention.

Authors:  P J Young; S A Ridley
Journal:  Anaesthesia       Date:  1999-12       Impact factor: 6.955

2.  Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription.

Authors:  N Singh; P Rogers; C W Atwood; M M Wagener; V L Yu
Journal:  Am J Respir Crit Care Med       Date:  2000-08       Impact factor: 21.405

Review 3.  An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients.

Authors:  Dimitrios K Matthaiou; Georgia Ntani; Marina Kontogiorgi; Garyfallia Poulakou; Apostolos Armaganidis; George Dimopoulos
Journal:  Intensive Care Med       Date:  2012-04-27       Impact factor: 17.440

4.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

5.  Short course antibiotic therapy for Gram-negative hospital-acquired pneumonia in the critically ill.

Authors:  R J Pugh; R P D Cooke; G Dempsey
Journal:  J Hosp Infect       Date:  2010-03-04       Impact factor: 3.926

6.  Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial.

Authors:  Lila Bouadma; Charles-Edouard Luyt; Florence Tubach; Christophe Cracco; Antonio Alvarez; Carole Schwebel; Frédérique Schortgen; Sigismond Lasocki; Benoît Veber; Monique Dehoux; Maguy Bernard; Blandine Pasquet; Bernard Régnier; Christian Brun-Buisson; Jean Chastre; Michel Wolff
Journal:  Lancet       Date:  2010-01-25       Impact factor: 79.321

7.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

Authors:  Jean Chastre; Michel Wolff; Jean-Yves Fagon; Sylvie Chevret; Franck Thomas; Delphine Wermert; Eva Clementi; Jesus Gonzalez; Dominique Jusserand; Pierre Asfar; Dominique Perrin; Fabienne Fieux; Sylvie Aubas
Journal:  JAMA       Date:  2003-11-19       Impact factor: 56.272

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.